LUMIGANCopy

• DRUGBANK - Bimatoprost
• indication:

  For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

• pharmacology:

• mechanism:

  Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Bimatoprost is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. Bimatoprost may also lower the rate of aqueous formation in the eye. Both these effects decrease the pressure within the eye.

• toxicity:

  In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m<sup>2</sup> is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.

• absorprion:

  Systemically absorbed when administered to the eye.

• halflife:

  Elimination half-life is approximately 45 minutes.

• roouteelimination:

  Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.

• volumedistribution:

  * 0.67 L/kg

• clearance:

  * 1.5 L/hr/kg [Healthy subjects receiving IV administration of 3.12 ug/kg]